A novel series of N1-methyl-(2-phenylindol-3-yl)glyoxylamides, 19-31, designed in accordance with our previously reported pharmacophore/ topological model, showed high affinity for the 18 kDa translocator protein (TSPO) and paved the way for developing a new radiolabeled probe. Thus ligand 31, N,N-di-n-propyl-(N1-methyl-2-(4′-nitrophenyl)indol-3-yl) glyoxylamide, featuring the best combination of affinity and lipophilicity, was labeled with carbon-11 for evaluation with positron emission tomography (PET) in monkey. After intravenous injection, [11C]31 entered brain to give a high proportion of TSPO-specific binding. These findings augur well for the future application of [11C]31 in humans. Consequently, the binding of 31 to human TSPO was tested on samples of brain membranes from deceased subjects who through ethically approved in vitro study had previously been established to be high-affinity binders (HABs), mixed-affinity binders (MABs), or low-affinity binders (LABs) for the known TSPO ligand, PBR28 (2). 31 showed high affinity for HABs, MABs, and LABs. In conclusion, [11C]31 represents a promising new chemotype for developing novel TSPO radioligands as biomarkers of neuroinflammation.

Evaluation of Novel N1-Methyl-2-phenylindol-3-ylglyoxylamides as a New Chemotype 2 of 18 kDa Translocator Protein-Selective Ligand Suitable for the Development 3 of Positron Emission Tomography Radioligands.,

TALIANI, SABRINA
Secondo
;
DA POZZO, ELEONORA;MARTINI, CLAUDIA
Penultimo
;
DA SETTIMO PASSETTI, FEDERICO
Ultimo
2011

Abstract

A novel series of N1-methyl-(2-phenylindol-3-yl)glyoxylamides, 19-31, designed in accordance with our previously reported pharmacophore/ topological model, showed high affinity for the 18 kDa translocator protein (TSPO) and paved the way for developing a new radiolabeled probe. Thus ligand 31, N,N-di-n-propyl-(N1-methyl-2-(4′-nitrophenyl)indol-3-yl) glyoxylamide, featuring the best combination of affinity and lipophilicity, was labeled with carbon-11 for evaluation with positron emission tomography (PET) in monkey. After intravenous injection, [11C]31 entered brain to give a high proportion of TSPO-specific binding. These findings augur well for the future application of [11C]31 in humans. Consequently, the binding of 31 to human TSPO was tested on samples of brain membranes from deceased subjects who through ethically approved in vitro study had previously been established to be high-affinity binders (HABs), mixed-affinity binders (MABs), or low-affinity binders (LABs) for the known TSPO ligand, PBR28 (2). 31 showed high affinity for HABs, MABs, and LABs. In conclusion, [11C]31 represents a promising new chemotype for developing novel TSPO radioligands as biomarkers of neuroinflammation.
Pike, Vw; Taliani, Sabrina; Lohith, Tg; Owen, R; Pugliesi, I; DA POZZO, Eleonora; Hong, J; Zoghbi, Ss; Gunn, R; Parker, Ca; Rabiner, Ea; Fujita, M; Innis, Rb; Martini, Claudia; DA SETTIMO PASSETTI, Federico
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/200746
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 21
social impact